FDA Expands Regorafenib’s Indications: Treatment of Patients with Hepatocellular Carcinoma Previously Treated with Sorafenib

On 27 April, the U.S. Food and Drug Administration expanded the indications of regorafenib (STIVARGA®, Bayer HealthCare Pharmaceuticals Inc.) to include the treatment of patients with hepatocellular carcinoma (HCC) who have been previously treated with sorafenib.

Read the full article